IN THE SPECIFICATION:

Please delete the sequence listing filed with this application and insert the attached substitute sequence listing into the application at the appropriate location.

Please further amend the specification as follows:

Please delete paragraph [042] and replace it with the following paragraph:

[042] SEQ ID NO: 1 contains the following subparts: Nucleotides 1-1205 comprise the HLA-A2 promoter; nucleotides 1206-1265 the HLA-A2 leader sequence; nucleotides 1266-1565 the human β2 microgobulin cDNA; nucleotides 1566-1610 a $(Gly4Ser)_3$ linker **(SEQ ID NO: 4)**; nucleotides 1611-2440 a segment containing exon 2 and part of intron 3 of HLA-A2; and nucleotides 2441-4547 a segment containing part of intron 3, exons 4 to 8, and part of the 3'non-coding region of the H_2D^b gene.

Please delete paragraph [0104] and replace it with the following paragraph:

[0104] The *HLA-DRB1*0101*, *HLA-DRA*0101* and *HLA-A*0201* transgenes were detected by PCR. Tail-DNA was extracted after overnight incubation at 56°C in 100 mM NaCl, 50 mM Tris-HCl pH 7.2, 100 mM EDTA, 1 % SDS and 0.5 mg/ml proteinase K, followed by the addition of 250 µL of saturated NaCl solution and isopropanol precipitation. The samples were washed (3x) in 70 % ethanol and resuspended in 150 µl of 10 mM Tris-HCl, 1 mM EDTA pH 8. PCR conditions were: 1.5 mM $MgCl_2$, 1.25 U of Taq Polymerase, buffer supplied by the manufacturer (InVitrogen, Carlsbad, CA), 1

cycle (7 min, 94 °C), 40 cycles (30 sec, 94 °C ; 30 sec, 60 °C ; 1 min, 72 °C), 1 cycle (4 min, 72°C), using as forward and reverse primers, for *HHD* : 5'CAT TGA GAC AGA GCG CTT GGC ACA GAA GCA G 3' **(SEQ ID NO: 5)** and 5'GGA TGA CGT GAG TAA ACC TGA ATC TTT GGA GTA CGC 3' **(SEQ ID NO: 6)**, for *HLA-DRB1*0101* : 5'TTC TTC AAC GGG ACG GAG CGG GTG 3' **(SEQ ID NO: 7)** and 5'CTG CAC TGT GAA GCT CTC ACC AAC 3' **(SEQ ID NO: 8)**, and for *HLA-DRA*0101* : 5' CTC CAA GCC CTC TCC CAG AG 3' **(SEQ ID NO: 9)** and 5'ATG TGC CTT ACA GAG GCC CC 3' **(SEQ ID NO: 10)**.

Please delete paragraph [0110] and replace it with the following paragraph:

[0110] The HLA-A2 binding peptides $HBsAg_{348-357}$ GLSPTVWLSV **(SEQ ID NO: 11)** and $HBsAg_{335-343}$ WLSLLVPFV **(SEQ ID NO: 12)**, the H-2 Kb binding peptide $HBsAg_{371-378}$ ILSPFLPL **(SEQ ID NO: 13)**, the HLA-DR1 binding peptide $HBsAg_{180-195}$ QAGFFLLTRILTIPQS **(SEQ ID NO: 14)**, the H-2 IA^b binding peptide $HBsAg_{126-138}$ RGLYFPAGGSSSG **(SEQ ID NO: 15)** and the preS2 peptide $HBsAg_{109-134}$ MQWNSTTFHQTLQDPRVRGLYFPAGG **(SEQ ID NO: 16)** were synthesized by Neosystem (Strasbourg, France) and dissolved in PBS-10 % DMSO at a concentration of 1 mg/ml. The numbering of the amino acid sequence of peptides starts from the first methionine of the HBV *ayw* subtype preS1 domain.

Please delete paragraph [0130] and replace it with the following paragraph:

[0130] Additional data obtained from these mice is provided in the following Tables 1-3.

Table 1. Proliferative responses of T CD4+ against HBV virus envelope HLA-DR1 epitopes from HLA-A2+DR1+H-2 CI-CII-transgenic mice injected with pcmv S2-S **(SEQ ID NOS 16, 17, 14 & 18)**

position	Amino Acid sequence	Responder/tested mice index	Stimulation
109-134	MQWNSTTFHQTLQDPRVRGLYFPAGG	(12/12)	3-4
200-214	TSLNFLGGTTVCLGQ	(6/12)	3-4
16/31	QAGFFLLTRILTIPQS	(12/12)	3-6
337/357	SLLVPFVQWFVGLSPTVWLSV	(5/12)	4-5

Table 2. Cytolytic response to HLA-A2+DR1+H-2 CI-CII-transgenic mice injected with pcmv S2-S **(SEQ ID NOS 19 & 20)**

position	Amino Acid sequence	Responder/tested mice	Maximal lysis
348-357	GLSPTVWLS	(12/12)	20-70%
335-343	WLSLLVPVF	(4/12)	30%

Table 3. Anti-PreS2 Antibody response anti of HLA-A2+DR1+H-2 CI-CII transgenic mice injected with pcmv S2-S **(SEQ ID NO: 16)**

position	Amino Acid sequence	Responder/tested mice
preS2	MQWNSTTFHQTLQDPRVRGLYFPAGG	(9/12)

Example 5: Immune Response to HBsAg-DNA-Vaccine